Research Article
Clinical Efficacy of Fuzheng Guben Anticancer Decoction Combined with Taxol in Treating Ovarian Carcinoma and Its Effect on Complication Incidence
Table 2
Between-group comparison of T-cell subset levels (
±
s).
| T-cell subset | | Control | Experimental | t/P |
| CD3+ (%) | Before treatment | 46.55 ± 5.54 | 46.76 ± 5.60 | | After treatment | 52.03 ± 5.84 | 57.81 ± 6.02 | 4.359/<0.001 |
| CD4+ (%) | Before treatment | 32.74 ± 4.82 | 32.86 ± 4.85 | | After treatment | 37.13 ± 4.30 | 41.60 ± 4.76 | 4.407/<0.001 |
| CD8+ (%) | Before treatment | 32.60 ± 3.29 | 32.44 ± 3.18 | | After treatment | 33.82 ± 3.19 | 33.86 ± 3.21 | 0.056/0.956 |
| CD4+/CD8+ | Before treatment | 1.03 ± 0.03 | 1.04 ± 0.04 | | After treatment | 1.10 ± 0.05 | 1.25 ± 0.05 | 13.416/<0.001 |
|
|
indicated in the comparison of patients in the same group before and after treatment. |